{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:39:47Z","timestamp":1792744787377,"version":"4.5.0"},"reference-count":42,"publisher":"e-Century Publishing Corporation","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/mhwb5732","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T08:00:37Z","timestamp":1772697637000},"page":"593-604","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of recombinant human endostatin injection plus immune checkpoint inhibitors for non-small cell lung cancer: a single-centered, retrospective study"],"prefix":"10.62347","volume":"16","author":[{"given":"Fei","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2026]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","unstructured":"Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, Tan DSW, Veronesi G and Reck M. Non-small-cell lung cancer. Nat Rev Dis Primers 2024; 10: 71.","journal-title":"Nat Rev Dis Primers"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"ML","year":"2024","unstructured":"Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, Jänne PA, Peters S and Hirsch FR. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet 2024; 404: 803-822.","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Alduais Y, Zhang H, Fan F, Chen J and Chen B. Non-small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment. Medicine (Baltimore) 2023; 102: e32899.","DOI":"10.1097\/MD.0000000000032899"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","unstructured":"Lu S, Zhang W, Wu L, Wang W, Zhang P, Fang W, Xing W, Chen Q, Yang L, Mei J, Tan L, Sun X, Xu S, Hu X, Yu G, Yu D, Yang N, Chen Y, Shan J, Xing L, Tian H, Zhang X, Zhou M, Fang H, Wu G, Liu Y, Ye M, Cao L, Jiang J, Li X, Zhu L, Li S, Kang M, Zhong A, Chen K, Wu N, Sun Q, Ma H, Cai K, Wang C, Lin G, Zhu K, Zhang Y, Zhang X, Hu H, Zhang W, Chen J, Yang Z, Hang X, Hu J, Huang Y, Zhang Z, Zhang L, Zhang L, Liu L, Lin D, Zhang J, Chen G, Li Y, Zhu L, Wang W, Yu W, Cao D, Keegan P and Yao S. Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial. JAMA 2024; 331: 201-211.","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/lctt.s235102","article-title":"Recognizing prognostic and predictive biomarkers in the treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs)","volume":"12","author":"Giustini","year":"2021","unstructured":"Giustini N and Bazhenova L. Recognizing prognostic and predictive biomarkers in the treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs). Lung Cancer (Auckl) 2021; 12: 21-34.","journal-title":"Lung Cancer (Auckl)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.3390\/ijms232315056","article-title":"Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance","volume":"23","author":"Wu","year":"2022","unstructured":"Wu J and Lin Z. Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance. Int J Mol Sci 2022; 23: 15056.","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/cells11030320","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects","volume":"11","author":"Tang","year":"2022","unstructured":"Tang S, Qin C, Hu H, Liu T, He Y, Guo H, Yan H, Zhang J, Tang S and Zhou H. Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects. Cells 2022; 11: 320.","journal-title":"Cells"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.21037\/atm-22-4218","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review","volume":"11","author":"Olivares-Hern&#xE1","year":"2023","unstructured":"Olivares-Hernández A, González Del Portillo E, Tamayo-Velasco Á, Figuero-Pérez L, Zhilina-Zhilina S, Fonseca-Sánchez E and Miramontes-González JP. Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review. Ann Transl Med 2023; 11: 354.","journal-title":"Ann Transl Med"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Mathew D, Marmarelis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, Ngiow SF, Klapholz M, Jun S, Zhang Z, Zorc R, Davis CW, Diehn M, Giles JR, Huang AC, Hwang WT, Zhang NR, Schoenfeld AJ, Carpenter EL, Langer CJ, Wherry EJ and Minn AJ. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science 2024; 384: eadf1329.","DOI":"10.1126\/science.adf1329"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","article-title":"Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels","volume":"8","author":"Ricciuti","year":"2022","unstructured":"Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, Leonardi GC, Plodkowski AJ, Gupta H, Cherniack AD, Tolstorukov MY, Sharma B, Felt KD, Gainor JF, Ravi A, Getz G, Schalper KA, Henick B, Forde P, Anagnostou V, Jänne PA, Van Allen EM, Nishino M, Sholl LM, Christiani DC, Lin X, Rodig SJ, Hellmann MD and Awad MM. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol 2022; 8: 1160-1168.","journal-title":"JAMA Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12032-023-02245-w","article-title":"Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status","volume":"41","author":"Anakha","year":"2023","unstructured":"Anakha J, Dobariya P, Sharma SS and Pande AH. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status. Med Oncol 2023; 41: 24.","journal-title":"Med Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2217\/fon-2021-1239","article-title":"Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer","volume":"18","author":"Zhu","year":"2022","unstructured":"Zhu J, Chen G, Niu K, Feng Y, Xie L, Qin S, Wang Z, Li J, Lang S, Zhuo W, Chen Z and Sun J. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer. Future Oncol 2022; 18: 1077-1087.","journal-title":"Future Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.21037\/jtd-2025-1223","article-title":"Combining recombinant human endostatin with third-generation EGFR-TKIs in advanced EGFR-sensitive mutant non-small cell lung cancer","volume":"17","author":"Chen","year":"2025","unstructured":"Chen J, Huang H, Zhong P, Lu Z, Ding X, Peng S, Zhu X, Wang F, Kong P, Tan AC, Song T, Xiao F and Chen L. Combining recombinant human endostatin with third-generation EGFR-TKIs in advanced EGFR-sensitive mutant non-small cell lung cancer. J Thorac Dis 2025; 17: 5223-5237.","journal-title":"J Thorac Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41598-024-83947-7","article-title":"Analysis of ICIs alone or in combination rechallenged outcomes after progression from first-line ICIs plus chemotherapy in patients with advanced non-small cell lung cancer","volume":"15","author":"Yin","year":"2025","unstructured":"Yin G, Liu X, Yu X, Tan S and Liu F. Analysis of ICIs alone or in combination rechallenged outcomes after progression from first-line ICIs plus chemotherapy in patients with advanced non-small cell lung cancer. Sci Rep 2025; 15: 30.","journal-title":"Sci Rep"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s00262-020-02641-5","article-title":"Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer","volume":"69","author":"Yang","year":"2020","unstructured":"Yang Y, Li L, Jiang Z, Wang B and Pan Z. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer. Cancer Immunol Immunother 2020; 69: 2523-2532.","journal-title":"Cancer Immunol Immunother"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"109746","DOI":"10.1016\/j.biopha.2019.109746","article-title":"Synergic effect of PD-1 blockade and endostar on the PI3K\/AKT\/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model","volume":"125","author":"Wu","year":"2020","unstructured":"Wu J, Zhao X, Sun Q, Jiang Y, Zhang W, Luo J and Li Y. Synergic effect of PD-1 blockade and endostar on the PI3K\/AKT\/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model. Biomed Pharmacother 2020; 125: 109746.","journal-title":"Biomed Pharmacother"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0640","article-title":"Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer","volume":"7","author":"Zhao","year":"2019","unstructured":"Zhao S, Ren S, Jiang T, Zhu B, Li X, Zhao C, Jia Y, Shi J, Zhang L, Liu X, Qiao M, Chen X, Su C, Yu H, Zhou C, Zhang J, Camidge DR and Hirsch FR. Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer. Cancer Immunol Res 2019; 7: 630-643.","journal-title":"Cancer Immunol Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1158\/2326-6066.CIR-18-0865","article-title":"Tumor vessel normalization, immunostimulatory reprogramming, and improved survival in glioblastoma with combined inhibition of PD-1, angiopoietin-2, and VEGF","volume":"7","author":"Tacchio M","year":"2019","unstructured":"Di Tacchio M, Macas J, Weissenberger J, Sommer K, Bähr O, Steinbach JP, Senft C, Seifert V, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Scheel AH, Büttner R, Grauer OM, Schittenhelm J, Tabatabai G, Harter PN, Günther S, Devraj K, Plate KH and Reiss Y. Tumor vessel normalization, immunostimulatory reprogramming, and improved survival in glioblastoma with combined inhibition of PD-1, angiopoietin-2, and VEGF. Cancer Immunol Res 2019; 7: 1910-1927.","journal-title":"Cancer Immunol Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"MA","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A and Reck M. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018; 378: 2288-2301.","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"7707","DOI":"10.2147\/CMAR.S212238","article-title":"Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer","volume":"11","author":"Liang","year":"2019","unstructured":"Liang H and Wang M. Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer. Cancer Manag Res 2019; 11: 7707-7719.","journal-title":"Cancer Manag Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jtho.2016.10.003","article-title":"The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC","volume":"12","author":"Manegold","year":"2017","unstructured":"Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Yang JC, Zhou C and Vokes E. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol 2017; 12: 194-207.","journal-title":"J Thorac Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","unstructured":"Khan KA and Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol 2018; 15: 310-324.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","article-title":"Improving immune-vascular crosstalk for cancer immunotherapy","volume":"18","author":"Huang","year":"2018","unstructured":"Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL and Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol 2018; 18: 195-203.","journal-title":"Nat Rev Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: first global approval","volume":"79","author":"Markham","year":"2019","unstructured":"Markham A and Keam SJ. Camrelizumab: first global approval. Drugs 2019; 79: 1355-1361.","journal-title":"Drugs"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: first global approval","volume":"79","author":"Hoy","year":"2019","unstructured":"Hoy SM. Sintilimab: first global approval. Drugs 2019; 79: 341-346.","journal-title":"Drugs"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","article-title":"Evaluation of dosing strategy for pembrolizumab for oncology indications","volume":"5","author":"Freshwater","year":"2017","unstructured":"Freshwater T, Kondic A, Ahamadi M, Li CH, de Greef R, de Alwis D and Stone JA. Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer 2017; 5: 43.","journal-title":"J Immunother Cancer"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"10732748221111296","DOI":"10.1177\/10732748221111296","article-title":"Tislelizumab: a modified anti-tumor programmed death receptor 1 antibody","volume":"29","author":"Zhang","year":"2022","unstructured":"Zhang L, Geng Z, Hao B and Geng Q. Tislelizumab: a modified anti-tumor programmed death receptor 1 antibody. Cancer Control 2022; 29: 10732748221111296.","journal-title":"Cancer Control"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jtho.2022.11.030","article-title":"Tobacco smoking-related mutational signatures in classifying smoking-associated and nonsmoking-associated NSCLC","volume":"18","author":"SM","year":"2023","unstructured":"Ernst SM, Mankor JM, van Riet J, von der Thüsen JH, Dubbink HJ, Aerts J, de Langen AJ, Smit EF, Dingemans AC and Monkhorst K. Tobacco smoking-related mutational signatures in classifying smoking-associated and nonsmoking-associated NSCLC. J Thorac Oncol 2023; 18: 487-498.","journal-title":"J Thorac Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3390\/jcm14031025","article-title":"NSCLC: current evidence on its pathogenesis, integrated treatment, and future perspectives","volume":"14","author":"Tahayneh","year":"2025","unstructured":"Tahayneh K, Idkedek M and Abu Akar F. NSCLC: current evidence on its pathogenesis, integrated treatment, and future perspectives. J Clin Med 2025; 14: 1025.","journal-title":"J Clin Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/COC.0000000000001088","article-title":"Advancements in NSCLC: from pathophysiological insights to targeted treatments","volume":"47","author":"Xu","year":"2024","unstructured":"Xu J, Tian L, Qi W, Lv Q and Wang T. Advancements in NSCLC: from pathophysiological insights to targeted treatments. Am J Clin Oncol 2024; 47: 291-303.","journal-title":"Am J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"761042","DOI":"10.3389\/fonc.2021.761042","article-title":"“How long have i got?” in stage IV NSCLC patients with at least 3 months up to 10 years survival, accuracy of long-, intermediate-, and short-term survival prediction is not good enough to answer this question","volume":"11","author":"Guo","year":"2021","unstructured":"Guo H, Li H, Zhu L, Feng J, Huang X and Baak JPA. “How long have i got?” in stage IV NSCLC patients with at least 3 months up to 10 years survival, accuracy of long-, intermediate-, and short-term survival prediction is not good enough to answer this question. Front Oncol 2021; 11: 761042.","journal-title":"Front Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50","volume":"39","author":"Reck","year":"2021","unstructured":"Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leal TA, Riess JW, Jensen E, Zhao B, Pietanza MC and Brahmer JR. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol 2021; 39: 2339-2349.","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1158\/1078-0432.CCR-21-3646","article-title":"Continuation of pembrolizumab with additional chemotherapy after progression with PD-1\/PD-L1 inhibitor monotherapy in patients with advanced NSCLC: a randomized, placebo-controlled phase II study","volume":"28","author":"Jung","year":"2022","unstructured":"Jung HA, Park S, Choi YL, Lee SH, Ahn JS, Ahn MJ and Sun JM. Continuation of pembrolizumab with additional chemotherapy after progression with PD-1\/PD-L1 inhibitor monotherapy in patients with advanced NSCLC: a randomized, placebo-controlled phase II study. Clin Cancer Res 2022; 28: 2321-2328.","journal-title":"Clin Cancer Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.radonc.2022.06.022","article-title":"Efficacy and safety of recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer","volume":"174","author":"Chen","year":"2022","unstructured":"Chen L, Tong F, Peng L, Huang Y, Yin P, Feng Y, Cheng S, Wang J and Dong X. Efficacy and safety of recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer. Radiother Oncol 2022; 174: 44-51.","journal-title":"Radiother Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1002\/ijc.31217","article-title":"A randomized phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first-line therapy for patients with breast cancer (CBCRT01)","volume":"142","author":"Chen","year":"2018","unstructured":"Chen J, Yao Q, Huang M, Wang B, Zhang J, Wang T, Ming Y, Zhou X, Jia Q, Huan Y, Wang J and Wang L. A randomized phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first-line therapy for patients with breast cancer (CBCRT01). Int J Cancer 2018; 142: 2130-2138.","journal-title":"Int J Cancer"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13550-023-00976-5","article-title":"Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET\/CT and serum tumor markers CYFRA21-1 and SCC-Ag","volume":"13","author":"Jiang","year":"2023","unstructured":"Jiang M, Chen P, Guo X, Zhang X, Gao Q, Zhang J, Zhao G and Zheng J. Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET\/CT and serum tumor markers CYFRA21-1 and SCC-Ag. EJNMMI Res 2023; 13: 27.","journal-title":"EJNMMI Res"},{"key":"ref36","unstructured":"Mo J, Zhang S, Liang X, Li C, Zhang H, Huang Z, Wen H and Lin W. Clinical study on Zhuang medicine Fuzheng compound in the treatment of advanced epidermal growth factor receptor sensitive mutant non-small cell lung cancer. International Journal of Traditional Chinese Medicine 2022; 1102-1106."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1210267","DOI":"10.3389\/fonc.2023.1210267","article-title":"Efficacy and safety of immune checkpoint inhibitors plus recombinant human endostatin therapy as second-line treatment in advanced non-small-cell lung cancer with negative driver gene: a pilot study","volume":"13","author":"Yang","year":"2023","unstructured":"Yang B, Li Y, Deng J, Yang H and Sun X. Efficacy and safety of immune checkpoint inhibitors plus recombinant human endostatin therapy as second-line treatment in advanced non-small-cell lung cancer with negative driver gene: a pilot study. Front Oncol 2023; 13: 1210267.","journal-title":"Front Oncol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00432-020-03380-x","article-title":"Anti-PD-1\/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma","volume":"147","author":"Huang","year":"2021","unstructured":"Huang D, Cui P, Huang Z, Wu Z, Tao H, Zhang S, Xiang R and Hu Y. Anti-PD-1\/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma. J Cancer Res Clin Oncol 2021; 147: 881-891.","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)","volume":"35","author":"Horn","year":"2017","unstructured":"Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J and Eberhardt WEE. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 2017; 35: 3924-3933.","journal-title":"J Clin Oncol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A and Gandara DR. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017; 389: 255-265.","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.15171\/apb.2017.004","article-title":"The challenges of recombinant endostatin in clinical application: focus on the different expression systems and molecular bioengineering","volume":"7","author":"Mohajeri","year":"2017","unstructured":"Mohajeri A, Sanaei S, Kiafar F, Fattahi A, Khalili M and Zarghami N. The challenges of recombinant endostatin in clinical application: focus on the different expression systems and molecular bioengineering. Adv Pharm Bull 2017; 7: 21-34.","journal-title":"Adv Pharm Bull"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:09:07Z","timestamp":1792742947000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/16\/2\/ajcr0170269.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.62347\/mhwb5732","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}